Dr. Mauro Discusses Updates in CML

Michael J. Mauro, MD, a hematologist and leader of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center, discusses updates in chronic myeloid leukemia (CML).

There are now 4 agents approved in the frontline setting for chronic phase CML. Mauro says that novel treatments in the frontline setting for CML were a big topic during the 2017 ASH Annual Meeting, and the FDA approval of bosutinib (Bosulif) as a first-line treatment for patients with Philadelphia chromosome-positive (Ph+) solidified that.

Mauro says that another important topic in CML is how to conceptualize treatment-free remission. This is exciting, Mauro adds, because tyrosine kinase inhibitors (TKIs) have allowed patients to experience substantial remissions.

Additionally, cardio-oncology is an important consideration for physicians treating patients with CML, Mauro says, as well as investigating fourth-generation drugs.